object
evalu
clinic
efficaci
safeti
acid
ala
critic
ill
patient
coronaviru
diseas
sinc
decemb
novel
coronaviru
pneumonia
induc
sever
acut
respiratori
coronaviru
becom
worldwid
pandem
overwhelm
health
care
system
global
thu
far
therapeut
yet
proven
effect
treatment
sever
mortal
rate
sever
patient
high
patholog
result
suggest
lung
display
diffus
alveolar
damag
addit
interstiti
mononuclear
inflammatori
infiltr
mainli
lymphocyt
observ
lung
moreov
sever
studi
shown
crp
ddimer
serum
proinflammatori
cytokin
etc
increas
patient
sever
find
suggest
cytokin
releas
syndrom
cr
may
associ
cr
system
inflammatori
respons
induc
infect
certain
drug
sharp
increas
proinflammatori
cytokin
main
manifest
caus
damag
heart
lung
organ
therefor
regul
system
inflammatori
respons
may
key
method
treat
patient
sever
clinic
studi
target
cr
conduct
viral
infect
also
caus
product
reactiv
oxygen
speci
ro
ro
play
import
role
viru
replic
invas
organ
damag
system
inflammatori
respons
acid
ala
antioxid
confirm
reduc
system
inflammatori
respons
patient
acut
coronari
syndrom
liver
transplant
patient
kidneypancrea
combin
transplant
patient
therefor
aim
studi
investig
whether
ala
could
allevi
system
inflammatori
respons
reduc
ro
product
therebi
improv
organ
function
prognosi
critic
ill
patient
studi
random
singleblind
group
sequenti
activecontrol
trial
particip
recruit
februari
march
particip
critic
ill
hospit
jinyintan
hospit
wuhan
china
enrol
ethic
approv
obtain
institut
ethic
committe
zhongshan
hospit
inform
consent
sign
particip
trial
regist
chines
clinic
trial
registri
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
patient
allerg
ala
similar
drug
b
vitamin
intoler
recommend
dosag
ala
past
histori
immun
system
diseas
diseas
close
relat
immun
system
figur
use
mix
random
unpredict
alloc
sequenc
alloc
sequenc
place
seal
opaqu
envelop
randomli
assign
critic
ill
patient
treatment
group
control
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
group
ratio
blind
save
research
complet
databas
final
unlock
particip
studi
personnel
awar
studygroup
assign
outcom
adjud
patient
treatment
group
treat
ala
mgd
intraven
infus
daili
plu
day
top
standard
medic
care
patient
control
group
treat
equal
volum
salin
infus
top
standard
medic
care
day
ala
discontinu
treatment
plan
complet
patient
meet
halfway
withdraw
criteria
withdraw
criteria
subject
request
withdraw
trial
intoler
advers
event
advers
event
investig
believ
must
withdrawn
studi
treat
accord
protocol
poor
complianc
physician
believ
withdraw
trial
initi
investig
includ
onset
time
ct
result
nucleic
acid
test
result
previou
histori
heartrel
symptom
chest
tight
etc
nyha
classif
person
histori
comorbid
treatment
plan
comprehens
physic
examin
includ
blood
pressur
heart
rate
weight
oxygen
satur
measur
sequenti
organ
failur
estim
sofa
score
electrocardiogram
result
echocardiogram
result
laboratori
test
result
blood
routin
liver
kidney
function
electrolyt
blood
glucos
blood
lipid
crp
urin
pregnanc
test
women
brain
natriuret
peptid
myocardi
enzym
troponin
coagul
function
serum
inflammatori
factor
test
clinic
followup
period
day
follow
data
collect
patient
day
symptom
blood
pressur
heart
rate
fingertip
oxygen
satur
record
twice
daili
sofa
score
major
minor
endpoint
event
record
advers
event
record
laboratori
test
blood
routin
liver
kidney
function
electrolyt
myocardi
enzym
troponin
ntprobnp
cpr
coagul
primari
outcom
studi
sofa
score
secondari
outcom
allcaus
mortal
day
outcom
determin
independ
clinic
endpoint
determin
committe
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
estim
death
studi
would
power
detect
improv
surviv
ala
versu
standard
control
group
admiss
discharg
twosid
alpha
level
primari
secondari
endpoint
measur
intentiontotreat
popul
includ
patient
underw
random
kaplanmei
method
use
estim
timetoev
end
point
twosid
stratifi
logrank
test
lr
test
use
cox
regress
model
appli
estim
hazard
ratio
safeti
evalu
includ
patient
receiv
least
one
dose
studi
medic
continu
variabl
describ
use
mean
median
standard
deviat
examin
use
analysi
varianc
anova
wilcoxon
rank
sum
test
kruskalw
test
categor
variabl
describ
frequenc
assess
use
chisquar
test
fisher
exact
test
chang
laboratori
data
sign
examin
item
advers
event
treatment
two
group
analyz
safeti
indic
studi
estim
miss
data
statist
analysi
perform
use
sa
valu
p
consid
statist
signific
twosid
test
repres
confid
interv
total
elig
patient
critic
ill
enrol
studi
patient
assign
receiv
ala
patient
standard
care
alon
total
patient
men
age
rang
year
median
age
patient
year
interquartil
rang
iqr
year
tabl
signific
differ
group
demograph
characterist
baselin
laboratori
test
result
sofa
score
enrol
day
day
averag
sofa
score
placebo
group
increas
point
time
period
averag
sofa
score
ala
treatment
group
increas
point
figur
signific
differ
sofa
score
placebo
group
ala
group
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
sofa
score
followup
allcaus
mortal
placebo
group
ala
group
figur
allcaus
mortal
numer
lower
ala
group
placebo
group
borderlin
statist
signific
observ
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
overal
surviv
borderlin
signific
observ
ala
group
placebo
group
day
patient
follow
advers
event
unexpect
drugsrel
advers
event
occur
trial
studi
enrol
patient
critic
ill
wuhan
jinyintan
hospit
result
suggest
ala
treatment
might
abl
improv
surviv
rate
patient
critic
ill
slow
increas
sofa
score
paramet
reach
statist
signific
due
limit
patient
number
tendenc
improv
clear
see
protect
effici
ala
critic
ill
patient
might
explain
two
aspect
antioxid
antiinflamm
firstli
ala
could
amelior
virusinduc
organ
dysfunct
counteract
ro
ross
reveal
excess
superoxid
induc
influenza
viru
infect
could
caus
organ
injuri
could
allevi
inhibit
ro
product
besid
xian
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
colleagu
suggest
replic
influenza
viru
imped
overexpress
cuzn
superoxid
dismutas
one
antioxid
enzym
secondli
antiinflamm
effect
ala
verifi
seri
clinic
trial
ala
could
significantli
reduc
level
serum
inflammatori
cytokin
improv
symptom
sever
patient
acut
coronari
syndrom
etc
clinic
trial
design
dampen
inflammatori
respons
one
clinic
trial
report
neutral
tocilizumab
could
quick
control
high
fever
respiratori
symptom
patient
reveal
feasibl
antiinflamm
treatment
clinic
trial
hydroxychloroquin
combin
azithromycin
treatment
molina
et
al
n
focus
patient
mild
anoth
clinic
trial
focus
patient
sever
signific
differ
viral
rna
load
durat
viral
rna
detect
lopinavirritonavir
combin
treatment
group
control
group
lopinavirritonavir
treatment
group
present
lower
allcaus
mortal
day
p
thu
addit
antiviru
treatment
strategi
search
treatment
strategi
clinic
import
aim
allevi
complic
covid
patient
reduc
mortal
rate
patient
sever
critic
ill
also
essenti
trial
sever
limit
particular
trial
suffici
number
case
epidem
situat
wuhan
rapidli
control
trial
period
critic
ill
covid
patient
particip
clinic
trial
could
enrol
studi
critic
ill
covid
patient
enrol
studi
anoth
limit
use
allcaus
mortal
secondari
outcom
could
distinguish
death
due
primari
insult
secondari
bacteri
infect
common
late
phrase
critic
ill
patient
clinic
studi
need
verifi
promis
efficaci
ala
inject
patient
critic
ill
conclus
result
deriv
small
number
critic
ill
covid
patient
promis
hope
report
might
stimul
initi
clinic
studi
larger
patient
cohort
valid
role
ala
reduc
shortterm
mortal
rate
among
critic
ill
patient
